<DOC>
	<DOC>NCT01070784</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A current clinical diagnosis of COPD according to the guidelines (GOLD, JPS) Documented COPD symptoms for more than 2 years Prebronchodilator FEV1≦50% of predicted normal value, and postbronchodilator FEV1/FVC＜70% History and/or current clinical diagnosis of asthma and atopic diseases such as allergic rhinitis Subjects with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator COPD exacerbation during the runin period or within 4 weeks prior to registration, requiring hospitalization and/or treatment with systemic steroids.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Symbicort</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>COPD</keyword>
	<keyword>Japanese</keyword>
</DOC>